Does the media prefer IRON or KRYS?

In the previous week, Disc Medicine had 4 more articles in the media than Krystal Biotech. MarketBeat recorded 9 mentions for Disc Medicine and 5 mentions for Krystal Biotech. Krystal Biotech's average media sentiment score of 1.28 beat Disc Medicine's score of 0.06 indicating that Krystal Biotech is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Disc Medicine 2 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Krystal Biotech 4 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media prefer IRON or CYTK?

In the previous week, Cytokinetics had 7 more articles in the media than Disc Medicine. MarketBeat recorded 16 mentions for Cytokinetics and 9 mentions for Disc Medicine. Cytokinetics' average media sentiment score of 0.16 beat Disc Medicine's score of 0.06 indicating that Cytokinetics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Disc Medicine 2 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Cytokinetics 5 Very Positive mention(s) 3 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Which has higher earnings & valuation, NUVL or IRON?

Nuvalent is trading at a lower price-to-earnings ratio than Disc Medicine, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Nuvalent N/A N/A -$425.38M -$6.06 N/A Disc Medicine N/A N/A -$212.18M -$6.62 N/A

Is NUVL or IRON more profitable?

Disc Medicine's return on equity of -36.94% beat Nuvalent's return on equity. Company Net Margins Return on Equity Return on Assets Nuvalent N/A -40.11% -35.43% Disc Medicine N/A -36.94% -33.88%

Does the media prefer NUVL or IRON?

In the previous week, Disc Medicine had 6 more articles in the media than Nuvalent. MarketBeat recorded 9 mentions for Disc Medicine and 3 mentions for Nuvalent. Nuvalent's average media sentiment score of 0.64 beat Disc Medicine's score of 0.06 indicating that Nuvalent is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Nuvalent 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Disc Medicine 2 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Is PRAX or IRON more profitable?

Disc Medicine's return on equity of -36.94% beat Praxis Precision Medicines' return on equity. Company Net Margins Return on Equity Return on Assets Praxis Precision Medicines N/A -43.02% -40.22% Disc Medicine N/A -36.94% -33.88%

Does the media favor PRAX or IRON?

In the previous week, Praxis Precision Medicines had 2 more articles in the media than Disc Medicine. MarketBeat recorded 11 mentions for Praxis Precision Medicines and 9 mentions for Disc Medicine. Praxis Precision Medicines' average media sentiment score of 0.47 beat Disc Medicine's score of 0.06 indicating that Praxis Precision Medicines is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Praxis Precision Medicines 2 Very Positive mention(s) 1 Positive mention(s) 6 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral Disc Medicine 2 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Is SYRE or IRON more profitable?

Disc Medicine's return on equity of -36.94% beat Spyre Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Spyre Therapeutics N/A -42.88% -27.76% Disc Medicine N/A -36.94% -33.88%

Does the media favor SYRE or IRON?

In the previous week, Spyre Therapeutics had 2 more articles in the media than Disc Medicine. MarketBeat recorded 11 mentions for Spyre Therapeutics and 9 mentions for Disc Medicine. Spyre Therapeutics' average media sentiment score of 0.12 beat Disc Medicine's score of 0.06 indicating that Spyre Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Spyre Therapeutics 2 Very Positive mention(s) 1 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Disc Medicine 2 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Disc Medicine (IRON) Competitors

$76.26 0.00 (0.00%)

Closing price 07/2/2026 04:00 PM Eastern

Extended Trading

$76.33 +0.07 (+0.10%)

As of 07/2/2026 04:38 PM Eastern

Compare

IRON vs. KRYS, CYTK, NUVL, PRAX, and SYRE

Should you buy Disc Medicine stock or one of its competitors? MarketBeat compares Disc Medicine with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Disc Medicine include Krystal Biotech (KRYS), Cytokinetics (CYTK), Nuvalent (NUVL), Praxis Precision Medicines (PRAX), and Spyre Therapeutics (SYRE). These companies are all part of the "pharmaceutical products" industry.

How does Disc Medicine compare to Krystal Biotech?

Disc Medicine (NASDAQ:IRON) and Krystal Biotech (NASDAQ:KRYS) are both medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their institutional ownership, risk, media sentiment, analyst recommendations, profitability, earnings, dividends and valuation.

Krystal Biotech has higher revenue and earnings than Disc Medicine. Disc Medicine is trading at a lower price-to-earnings ratio than Krystal Biotech, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Disc Medicine	N/A	N/A	-$212.18M	-$6.62	N/A
Krystal Biotech	$389.13M	28.41	$204.83M	$7.48	50.14

Disc Medicine has a beta of 0.97, indicating that its share price is 3% less volatile than the broader market. Comparatively, Krystal Biotech has a beta of 0.5, indicating that its share price is 50% less volatile than the broader market.

83.7% of Disc Medicine shares are owned by institutional investors. Comparatively, 86.3% of Krystal Biotech shares are owned by institutional investors. 3.8% of Disc Medicine shares are owned by insiders. Comparatively, 13.1% of Krystal Biotech shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Krystal Biotech has a net margin of 53.92% compared to Disc Medicine's net margin of 0.00%. Krystal Biotech's return on equity of 19.25% beat Disc Medicine's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Disc Medicine	N/A	-36.94%	-33.88%
Krystal Biotech	53.92%	19.25%	17.62%

In the previous week, Disc Medicine had 4 more articles in the media than Krystal Biotech. MarketBeat recorded 9 mentions for Disc Medicine and 5 mentions for Krystal Biotech. Krystal Biotech's average media sentiment score of 1.28 beat Disc Medicine's score of 0.06 indicating that Krystal Biotech is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Disc Medicine	2 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Krystal Biotech	4 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Disc Medicine presently has a consensus price target of $104.44, indicating a potential upside of 36.96%. Krystal Biotech has a consensus price target of $340.56, indicating a potential downside of 9.20%. Given Disc Medicine's higher possible upside, equities analysts plainly believe Disc Medicine is more favorable than Krystal Biotech.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Disc Medicine	1 Sell rating(s)	1 Hold rating(s)	9 Buy rating(s)	0 Strong Buy rating(s)	2.73
Krystal Biotech	0 Sell rating(s)	2 Hold rating(s)	10 Buy rating(s)	0 Strong Buy rating(s)	2.83

Summary

Krystal Biotech beats Disc Medicine on 12 of the 15 factors compared between the two stocks.

How does Disc Medicine compare to Cytokinetics?

Disc Medicine (NASDAQ:IRON) and Cytokinetics (NASDAQ:CYTK) are both medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their valuation, risk, institutional ownership, dividends, profitability, analyst recommendations, earnings and media sentiment.

Disc Medicine currently has a consensus target price of $104.44, suggesting a potential upside of 36.96%. Cytokinetics has a consensus target price of $100.00, suggesting a potential upside of 15.62%. Given Disc Medicine's higher possible upside, equities research analysts clearly believe Disc Medicine is more favorable than Cytokinetics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Disc Medicine	1 Sell rating(s)	1 Hold rating(s)	9 Buy rating(s)	0 Strong Buy rating(s)	2.73
Cytokinetics	1 Sell rating(s)	2 Hold rating(s)	17 Buy rating(s)	2 Strong Buy rating(s)	2.91

Disc Medicine has a beta of 0.97, indicating that its share price is 3% less volatile than the broader market. Comparatively, Cytokinetics has a beta of 0.42, indicating that its share price is 58% less volatile than the broader market.

In the previous week, Cytokinetics had 7 more articles in the media than Disc Medicine. MarketBeat recorded 16 mentions for Cytokinetics and 9 mentions for Disc Medicine. Cytokinetics' average media sentiment score of 0.16 beat Disc Medicine's score of 0.06 indicating that Cytokinetics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Disc Medicine	2 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Cytokinetics	5 Very Positive mention(s)	3 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Disc Medicine has higher earnings, but lower revenue than Cytokinetics. Cytokinetics is trading at a lower price-to-earnings ratio than Disc Medicine, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Disc Medicine	N/A	N/A	-$212.18M	-$6.62	N/A
Cytokinetics	$88.04M	122.24	-$784.96M	-$6.84	N/A

83.7% of Disc Medicine shares are owned by institutional investors. 3.8% of Disc Medicine shares are owned by company insiders. Comparatively, 2.6% of Cytokinetics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Disc Medicine has a net margin of 0.00% compared to Cytokinetics' net margin of -784.02%. Cytokinetics' return on equity of 0.00% beat Disc Medicine's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Disc Medicine	N/A	-36.94%	-33.88%
Cytokinetics	-784.02%	N/A	-52.86%

Summary

Disc Medicine beats Cytokinetics on 9 of the 16 factors compared between the two stocks.

How does Disc Medicine compare to Nuvalent?

Nuvalent (NASDAQ:NUVL) and Disc Medicine (NASDAQ:IRON) are both mid-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their risk, institutional ownership, valuation, profitability, media sentiment, analyst recommendations, earnings and dividends.

Nuvalent presently has a consensus price target of $127.73, suggesting a potential upside of 3.23%. Disc Medicine has a consensus price target of $104.44, suggesting a potential upside of 36.96%. Given Disc Medicine's stronger consensus rating and higher probable upside, analysts plainly believe Disc Medicine is more favorable than Nuvalent.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Nuvalent	1 Sell rating(s)	15 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.15
Disc Medicine	1 Sell rating(s)	1 Hold rating(s)	9 Buy rating(s)	0 Strong Buy rating(s)	2.73

Nuvalent has a beta of 1.14, indicating that its stock price is 14% more volatile than the broader market. Comparatively, Disc Medicine has a beta of 0.97, indicating that its stock price is 3% less volatile than the broader market.

Nuvalent is trading at a lower price-to-earnings ratio than Disc Medicine, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Nuvalent	N/A	N/A	-$425.38M	-$6.06	N/A
Disc Medicine	N/A	N/A	-$212.18M	-$6.62	N/A

Disc Medicine's return on equity of -36.94% beat Nuvalent's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Nuvalent	N/A	-40.11%	-35.43%
Disc Medicine	N/A	-36.94%	-33.88%

97.3% of Nuvalent shares are owned by institutional investors. Comparatively, 83.7% of Disc Medicine shares are owned by institutional investors. 5.0% of Nuvalent shares are owned by insiders. Comparatively, 3.8% of Disc Medicine shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

In the previous week, Disc Medicine had 6 more articles in the media than Nuvalent. MarketBeat recorded 9 mentions for Disc Medicine and 3 mentions for Nuvalent. Nuvalent's average media sentiment score of 0.64 beat Disc Medicine's score of 0.06 indicating that Nuvalent is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Nuvalent	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Disc Medicine	2 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

Disc Medicine beats Nuvalent on 8 of the 13 factors compared between the two stocks.

How does Disc Medicine compare to Praxis Precision Medicines?

Praxis Precision Medicines (NASDAQ:PRAX) and Disc Medicine (NASDAQ:IRON) are both mid-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their profitability, dividends, institutional ownership, earnings, risk, media sentiment, analyst recommendations and valuation.

In the previous week, Praxis Precision Medicines had 2 more articles in the media than Disc Medicine. MarketBeat recorded 11 mentions for Praxis Precision Medicines and 9 mentions for Disc Medicine. Praxis Precision Medicines' average media sentiment score of 0.47 beat Disc Medicine's score of 0.06 indicating that Praxis Precision Medicines is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Praxis Precision Medicines	2 Very Positive mention(s)	1 Positive mention(s)	6 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
Disc Medicine	2 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

67.8% of Praxis Precision Medicines shares are held by institutional investors. Comparatively, 83.7% of Disc Medicine shares are held by institutional investors. 3.0% of Praxis Precision Medicines shares are held by insiders. Comparatively, 3.8% of Disc Medicine shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Disc Medicine has lower revenue, but higher earnings than Praxis Precision Medicines. Praxis Precision Medicines is trading at a lower price-to-earnings ratio than Disc Medicine, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Praxis Precision Medicines	$8.55M	1,038.64	-$303.27M	-$13.37	N/A
Disc Medicine	N/A	N/A	-$212.18M	-$6.62	N/A

Praxis Precision Medicines has a beta of 2.74, indicating that its stock price is 174% more volatile than the broader market. Comparatively, Disc Medicine has a beta of 0.97, indicating that its stock price is 3% less volatile than the broader market.

Praxis Precision Medicines presently has a consensus target price of $569.63, suggesting a potential upside of 78.84%. Disc Medicine has a consensus target price of $104.44, suggesting a potential upside of 36.96%. Given Praxis Precision Medicines' stronger consensus rating and higher possible upside, analysts clearly believe Praxis Precision Medicines is more favorable than Disc Medicine.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Praxis Precision Medicines	2 Sell rating(s)	1 Hold rating(s)	14 Buy rating(s)	4 Strong Buy rating(s)	2.95
Disc Medicine	1 Sell rating(s)	1 Hold rating(s)	9 Buy rating(s)	0 Strong Buy rating(s)	2.73

Disc Medicine's return on equity of -36.94% beat Praxis Precision Medicines' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Praxis Precision Medicines	N/A	-43.02%	-40.22%
Disc Medicine	N/A	-36.94%	-33.88%

Summary

Praxis Precision Medicines beats Disc Medicine on 8 of the 15 factors compared between the two stocks.

How does Disc Medicine compare to Spyre Therapeutics?

Spyre Therapeutics (NASDAQ:SYRE) and Disc Medicine (NASDAQ:IRON) are both mid-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their valuation, institutional ownership, risk, earnings, analyst recommendations, dividends, media sentiment and profitability.

Spyre Therapeutics currently has a consensus price target of $95.83, suggesting a potential upside of 10.62%. Disc Medicine has a consensus price target of $104.44, suggesting a potential upside of 36.96%. Given Disc Medicine's higher probable upside, analysts plainly believe Disc Medicine is more favorable than Spyre Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Spyre Therapeutics	1 Sell rating(s)	0 Hold rating(s)	10 Buy rating(s)	2 Strong Buy rating(s)	3.00
Disc Medicine	1 Sell rating(s)	1 Hold rating(s)	9 Buy rating(s)	0 Strong Buy rating(s)	2.73

Spyre Therapeutics has a beta of 3.02, indicating that its stock price is 202% more volatile than the broader market. Comparatively, Disc Medicine has a beta of 0.97, indicating that its stock price is 3% less volatile than the broader market.

Spyre Therapeutics has higher revenue and earnings than Disc Medicine. Spyre Therapeutics is trading at a lower price-to-earnings ratio than Disc Medicine, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Spyre Therapeutics	$890K	8,559.82	-$155.20M	-$2.08	N/A
Disc Medicine	N/A	N/A	-$212.18M	-$6.62	N/A

Disc Medicine's return on equity of -36.94% beat Spyre Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Spyre Therapeutics	N/A	-42.88%	-27.76%
Disc Medicine	N/A	-36.94%	-33.88%

80.4% of Spyre Therapeutics shares are held by institutional investors. Comparatively, 83.7% of Disc Medicine shares are held by institutional investors. 15.7% of Spyre Therapeutics shares are held by company insiders. Comparatively, 3.8% of Disc Medicine shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

In the previous week, Spyre Therapeutics had 2 more articles in the media than Disc Medicine. MarketBeat recorded 11 mentions for Spyre Therapeutics and 9 mentions for Disc Medicine. Spyre Therapeutics' average media sentiment score of 0.12 beat Disc Medicine's score of 0.06 indicating that Spyre Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Spyre Therapeutics	2 Very Positive mention(s)	1 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Disc Medicine	2 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

Spyre Therapeutics beats Disc Medicine on 11 of the 15 factors compared between the two stocks.

Get Disc Medicine News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding IRON and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

IRON vs. The Competition

Export

Metric	Disc Medicine	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$2.91B	$3.78B	$7.18B	$12.47B
Dividend Yield	N/A	2.16%	2.67%	6.50%
P/E Ratio	-11.52	21.61	28.02	24.70
Price / Sales	N/A	325.90	532.59	98.61
Price / Cash	N/A	147.12	49.26	57.09
Price / Book	3.91	8.66	10.96	6.46
Net Income	-$212.18M	$23.81M	$3.57B	$337.01M
7 Day Performance	1.98%	3.39%	2.12%	1.69%
1 Month Performance	13.82%	10.81%	5.25%	3.81%
1 Year Performance	39.30%	62.61%	33.29%	23.90%

Disc Medicine Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
IRON Disc Medicine	2.3412 of 5 stars	$76.26 flat	$104.44 +37.0%	+39.3%	$2.91B	N/A	N/A	30	Insider Trade
KRYS Krystal Biotech	2.5462 of 5 stars	$340.21 -0.9%	$340.56 +0.1%	+162.3%	$10.03B	$417.30M	45.48	210	Positive News Analyst Downgrade
CYTK Cytokinetics	2.7242 of 5 stars	$80.01 +1.1%	$99.30 +24.1%	+155.1%	$9.96B	$88.04M	N/A	250	Insider Trade
NUVL Nuvalent	2.5294 of 5 stars	$123.44 +0.0%	$131.15 +6.2%	+54.0%	$9.75B	N/A	N/A	40	Short Interest Decrease
PRAX Praxis Precision Medicines	3.7322 of 5 stars	$305.37 +0.7%	$566.21 +85.4%	+573.8%	$8.51B	$8.55M	N/A	110

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:IRON) was last updated on 7/5/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Disc Medicine (IRON) Competitors

IRON vs. KRYS, CYTK, NUVL, PRAX, and SYRE

How does Disc Medicine compare to Krystal Biotech?

Summary

How does Disc Medicine compare to Cytokinetics?

Summary

How does Disc Medicine compare to Nuvalent?

Summary

How does Disc Medicine compare to Praxis Precision Medicines?

Summary

How does Disc Medicine compare to Spyre Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

IRON vs. The Competition

Disc Medicine Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Disc Medicine (IRON) Competitors

IRON vs. KRYS, CYTK, NUVL, PRAX, and SYRE

How does Disc Medicine compare to Krystal Biotech?

Which has stronger valuation & earnings, IRON or KRYS?

Which has more risk & volatility, IRON or KRYS?

Do insiders and institutionals have more ownership in IRON or KRYS?

Is IRON or KRYS more profitable?

Does the media prefer IRON or KRYS?

Do analysts prefer IRON or KRYS?

Summary

How does Disc Medicine compare to Cytokinetics?

Do analysts rate IRON or CYTK?

Which has more volatility & risk, IRON or CYTK?

Does the media prefer IRON or CYTK?

Which has better earnings and valuation, IRON or CYTK?

Do insiders & institutionals have more ownership in IRON or CYTK?

Is IRON or CYTK more profitable?

Summary

How does Disc Medicine compare to Nuvalent?

Do analysts rate NUVL or IRON?

Which has more volatility and risk, NUVL or IRON?

Which has higher earnings & valuation, NUVL or IRON?

Is NUVL or IRON more profitable?

Do insiders and institutionals have more ownership in NUVL or IRON?

Does the media prefer NUVL or IRON?

Summary

How does Disc Medicine compare to Praxis Precision Medicines?

Does the media favor PRAX or IRON?

Do institutionals & insiders have more ownership in PRAX or IRON?

Which has stronger valuation and earnings, PRAX or IRON?

Which has more risk and volatility, PRAX or IRON?

Do analysts recommend PRAX or IRON?

Is PRAX or IRON more profitable?

Summary

How does Disc Medicine compare to Spyre Therapeutics?

Do analysts prefer SYRE or IRON?

Which has more volatility and risk, SYRE or IRON?

Which has better earnings & valuation, SYRE or IRON?

Is SYRE or IRON more profitable?

Do insiders & institutionals have more ownership in SYRE or IRON?

Does the media favor SYRE or IRON?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

IRON vs. The Competition

Disc Medicine Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools